{"id":"NCT04064411","sponsor":"Radius Health, Inc.","briefTitle":"Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis","officialTitle":"A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-08-05","primaryCompletion":"2021-10-05","completion":"2021-11-09","firstPosted":"2019-08-21","resultsPosted":"2023-02-15","lastUpdate":"2023-02-15"},"enrollment":511,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Postmenopausal Osteoporosis"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"abaloparatide","otherNames":["TYMLOSÂ®","BA058","abaloparatide-SC"]},{"type":"COMBINATION_PRODUCT","name":"abaloparatide solid microstructured transdermal system","otherNames":["BA058","abaloparatide-transdermal"]}],"arms":[{"label":"abaloparatide-SC","type":"ACTIVE_COMPARATOR"},{"label":"abaloparatide-sMTS","type":"EXPERIMENTAL"}],"summary":"A 12-month study to compare the efficacy and safety of abaloparatide-solid microstructured transdermal system (sMTS) with abaloparatide-subcutaneous (SC).","primaryOutcome":{"measure":"Percent Change From Baseline in Lumbar Spine BMD at Month 12","timeFrame":"Baseline, Month 12","effectByArm":[{"arm":"Abaloparatide-SC","deltaMin":10.8571,"sd":0.4755},{"arm":"Abaloparatide-sMTS","deltaMin":7.1361,"sd":0.4605}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"50 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":97,"countries":["United States","Denmark","Hungary","Poland","Puerto Rico"]},"refs":{"pmids":["37417725"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":254},"commonTop":["Application site erythema","Application site pain","Injection site erythema","Application site oedema","Application site swelling"]}}